HDFC Pharma and Healthcare Fund Direct Growth

HDFC Pharma and Healthcare Fund Direct Growth

Equity

Direct

Sector - Healthcare

NAV as on 20-01-2025

₹ 16.56

0.9%

1D

Inception Returns

47.9%

/yr

About HDFC Pharma and Healthcare Fund Direct Growth

HDFC Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 4 October, 2023. The fund is managed by . The fund could potentially beat inflation in the long-run.

Key Parameters

  1. HDFC Pharma and Healthcare Fund Direct Growth has ₹1577 Cr worth of assets under management (AUM) as on Nov 2024 and is less than category average.
  2. The fund has an expense ratio 0.9.

Returns

HDFC Pharma and Healthcare Fund Direct Growth has given a CAGR return of 47.87% since inception. Over the last 1 year the fund has given a CAGR return of 41.11%.

Holdings

HDFC Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Health, Cash Equivalent, Corporate, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Divi's Laboratories Ltd, Lupin Ltd, Aster DM Healthcare Ltd Ordinary Shares

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 15%
For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefit
Dividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.

Investment objective of HDFC Pharma and Healthcare Fund Direct Growth

To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 100.00 and for SIP is INR 100.00. HDFC Pharma and Healthcare Fund Direct Growth has no lock in period.

Historical NAV & Returns

Absolute

zero opening, trading, fund transfer fee
8477 people have invested ₹ 4.4Cr in HDFC Pharma and Healthcare Fund Direct Growth in the last three months

INDmoney Rank for HDFC Pharma and Healthcare Fund Direct Growth

Powered by IND quant engine
IND ranking is not available for this fund.
img
Among most bought funds within the category
img
No bad points found for this fund.

HDFC Pharma and Healthcare Fund Direct Growth Overview

Expense ratio0.91%
Benchmark
S&P BSE Healthcare PR
AUM₹1577 Cr
Inception Date4 October, 2023
Min Lumpsum/SIP₹100/₹100
Exit Load
1.0%
Lock InNo Lock-in
TurnOver
28.39%
STCGSelling mutual fund before 1 year, returns taxed at 20%.
LTCGAfter 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk
Risk meter
pointer
Very High Risk

Trailing Returns

as on (20-Jan-25)

Period
HDFC Pharma and Healthcare Fund Direct Growth
Nifty 500
sector - healthcare
1M
-0.9%
-4.7%
-1.9%
3M
0.4%
-7.5%
-3.7%
6M
20.5%
-5.1%
9.2%
1Y
41.1%
10.6%
30.5%

Fund Distribution

as on (30-Nov-24)

  • Equity 96.6%

  • Debt & Cash 2%

Large cap
36.8%

Small cap
31.5%

Mid cap
27.1%

Sector Allocation

Dec'24

Nov'24

Oct'24

Health
98.1%
Basic Materials
1.9%
All changes are between Sep'24 and Nov'24
Nov'24
Oct'24
Sep'24
Fund Returns
1.24%
1.02%
2.65%
Nifty 500
-0.60%
-6.52%
2.04%
  • This fund’s returns stands at 1.24% whereas the fund’s underlying benchmark Nifty 500 returns stands at -0.60% as on Nov'24
  • This fund outperformed Nifty 500 by 1.83% in Nov'24
Parameters
Dec'24
Nov'24
Oct'24
AUM
₹ 1.5K Cr
₹ 1.4K Cr
₹ 1.3K Cr
  • AUM of the fund stands at 1.5K Cr as of Dec'24
  • AUM increased by 77 Cr between Dec'24 and Nov'24
Top Stocks bought last month
Wockhardt Ltd's allocation increased from 2.52% to 3.3%
Wockhardt Ltd's allocation increased from 2.52% to 3.3%
Metropolis Healthcare Ltd's allocation increased from 2.2% to 2.95%
Metropolis Healthcare Ltd's allocation increased from 2.2% to 2.95%
Laurus Labs Ltd's allocation increased from 1.26% to 1.93%
Laurus Labs Ltd's allocation increased from 1.26% to 1.93%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 14.02 % to 13.48 %
Sun Pharmaceuticals Industries Ltd's allocation decreased from 14.02 % to 13.48 %
Divi's Laboratories Ltd's allocation decreased from 7.91 % to 7.85 %
Divi's Laboratories Ltd's allocation decreased from 7.91 % to 7.85 %
Cipla Ltd's allocation decreased from 8.17 % to 7.75 %
Cipla Ltd's allocation decreased from 8.17 % to 7.75 %
Cash allocation has gone up from 1.8% to 2%
Cash allocation has gone up from 1.8% to 2%

Top 3 Sectors in December were Health, Corporate & Basic Materials

Dec'24
Health
98%
Corporate
29%
Basic Materials
2%
Nov'24
Health
98%
Corporate
28%
Basic Materials
2%
  • Gainers

  • Losers

Fund
Nov'24
Oct'24
Sep'24
No of Holdings
32
33
35
Top 5 Company Concentration
38.9%
40.4%
33.8%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (13.5%)
Sun Pharmaceuticals Industries Ltd (14%)
Sun Pharmaceuticals Industries Ltd (11.6%)
No of Sectors
3
2
2
Top 5 Sectors Concentration
128.3%
100%
100%
Sector having highest exposure
Health (98%)
Health (98%)
Health (98.2%)
Loading...
We are taking more time than usual
Fund House
HDFC Asset Management Co Ltd
Total Schemes
Total AUM
₹7.98L Cr
as on 29-Nov-2024
Address
HDFC Asset Management Company Limited,“HUL House”, 2nd Floor,,H.T. Parekh Marg,165-166, Backbay Reclamation,,Churchgate,
Phone
+912266316333
Website
cliser@hdfcfund.com

HDFC Pharma and Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 47.87% since inception which is more than its category average return of 20.42%
Fund Allocations

Fund Allocations

This fund has an allocation of 96.64% in Equity, 0% in Debt and 1.96% in Cash related instruments
AUM size ₹1577 Cr

AUM size ₹1577 Cr

This fund has AUM of ₹1577 Cr which is less than its category average of ₹ 1963 Cr
Expense Ratio 0.91%

Expense Ratio 0.91%

This fund has an expense ratio of 0.91% which is less than its category average expense ratio of 1.4%

Frequently Asked Questions for HDFC Pharma and Healthcare Fund Direct Growth

The current NAV of HDFC Pharma and Healthcare Fund Direct Growth is ₹16.56 as on 20-Jan-2025.
Existing (Absolute + CAGR) as on 20-Jan-2025.
HDFC Pharma and Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
-0.86%
-0.86%
6 Month Returns
20.51%
20.51%
1 Year Returns
41.11%
41.11%
3 Years Returns
0%
0%
5 Years Returns
0%
0%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.91% as on December 2024
₹1577 Cr as on December 2024
Sun Pharmaceuticals Industries Ltd(13.22%), Cipla Ltd(7.89%), Divi's Laboratories Ltd(7.18%), Lupin Ltd(6.17%), Aster DM Healthcare Ltd Ordinary Shares(3.89%) as on December 2024
The alpha ratio for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
HDFC Pharma and Healthcare Fund Direct Growth
7.58
-
-
As on December 2024
The alpha for HDFC Pharma and Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
HDFC Pharma and Healthcare Fund Direct Growth
0.93
-
-
As on December 2024
The Beta for HDFC Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
HDFC Pharma and Healthcare Fund Direct Growth
2.95
-
-
As on December 2024
The sharpe ratio for HDFC Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
HDFC Pharma and Healthcare Fund Direct Growth
12.42
-
-
As on December 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
The Exit load of HDFC Pharma and Healthcare Fund Direct Growth is 1%